irinotecan - Generic mfg.
Cyramza (ramucirumab) - Eli Lilly
Re-evaluating the neutropenia-survival paradigm in irinotecan-based therapy for advanced gastric cancer: post-hoc analysis of the RINDBeRG trial. (PubMed, Int J Clin Oncol) - Oct 23, 2026 - "Unlike other cytotoxic regimens, CIN was not associated with survival in AGC patients receiving IRI with or without RAM. The clinical relevance of baseline ANC warrants further investigation." 
Journal • Retrospective data • Chemotherapy-Induced Neutropenia • Gastric Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor
http://www.ncbi.nlm.nih.gov/pubmed/42905384
 
Daisuke Sakai; Hironori Yamaguchi; Kei Muro; Shigenori Kadowaki; Shigeyuki Tamura; Taro Mizuno; Taroh Satoh; Tomoki Sakakida; Toshio Shimokawa; Yasunobu Ishizuka; Yukiya Narita
 
Oct 23, 2026
 
Prev Next